Brown Deborah Margaret 4

What Happened

• Deborah Margaret Brown, a director of Oncolytics Biotech Inc. (ONCY), was granted 30,000 derivative awards (stock options) on June 1, 2026. The Form 4 reports the acquisition as 30,000 shares @ $0.00 because the grant is a derivative; the exercise price is equal to the Nasdaq closing price on June 1, 2026 (no immediate intrinsic value reported).

Key Details

• Transaction date and filing: Grant dated 2026-06-01; Form 4 filed 2026-06-03 (timely within the 2-business-day requirement).
• Award size and economics: 30,000 options; exercise price = closing price on 2026-06-01 (per footnote). Form shows $0 value at grant because strike = market price.
• Vesting: Options vest in three equal annual installments; first tranche vests on 2027-06-01, subject to continued service (per footnote).
• Shares owned after transaction: Not disclosed in the filing.
• Filing timeliness/other codes: No 10b5-1 plan, tax withholding, or late filing indicated in the Form 4.

Context

• This was a grant of options (an award), not a purchase or sale. Because the exercise price equals the stock price at grant, the awards have no immediate intrinsic value; their future worth depends on ONCY's stock rising above the exercise price before or at exercise. Vesting over three years means the options become exercisable gradually and are contingent on continued service.